FindTrial
Sign In

ARV-471

DRUG9 trials

Sponsors

Arvinas Estrogen Receptor Inc., QuantumLeap Healthcare Collaborative, Pfizer, Arvinas Inc.

Conditions

Advanced Breast CancerAngiosarcomaBreast CancerBreast NeoplasmsBreast TumorsER+Early-stage Breast CancerHER2-negative Breast Cancer

Phase 1

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
Active, not recruitingNCT05548127
PfizerBreast Cancer
Start: 2023-02-23End: 2027-03-24Updated: 2026-09-02
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
TerminatedNCT05573555
PfizerBreast Cancer
Start: 2023-03-01End: 2026-10-06Updated: 2026-10-27
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults
CompletedNCT05652660
PfizerHealthy
Start: 2022-12-09End: 2023-03-06Updated: 2024-07-26
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults
CompletedNCT05673889
PfizerHealthy
Start: 2023-01-27End: 2023-04-19Updated: 2024-08-16
A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China
CompletedNCT05732428
PfizerBreast Cancer
Start: 2023-02-20End: 2024-11-01Updated: 2025-01-27
A Phase 1b Trial of ARV-471 in Combination with Everolimus in Patients with ER+, HER2– Advanced or Metastatic Breast Cancer
CompletedCTIS2024-513284-30-00
Arvinas Estrogen Receptor Inc.ER+, HER2– Advanced or Metastatic Breast Cancer
Start: 2023-03-22End: 2025-08-25Target: 1Updated: 2025-02-13

Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RecruitingNCT01042379
QuantumLeap Healthcare CollaborativeAngiosarcoma, Breast Cancer, Breast Neoplasms +8
Start: 2010-03-01End: 2031-12-01Target: 5000Updated: 2026-05-06
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
CompletedNCT05549505
Arvinas Inc.Breast Cancer
Start: 2023-02-15End: 2024-07-25Updated: 2025-08-29

Phase 3

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
Active, not recruitingNCT05654623
PfizerAdvanced Breast Cancer
Start: 2023-03-03End: 2028-05-15Updated: 2026-03-18

Related Papers

Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast Cancer
JAMA Oncology2026-10-22
Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer.
2026-08-06
Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial.
2026-08-03
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
2026-07-30
Neoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial.
Journal of Clinical Oncology2026-06-03
Impact of age on breast cancer outcomes in the neoadjuvant I-SPY2 trial.
Journal of Clinical Oncology2026-05-27
Taxane and platinum combination as a predictor of pathologic complete response in I-SPY2 by gene expression breast cancer signatures.
Journal of Clinical Oncology2026-05-27
Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus abemaciclib (ABE) in ER+/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): TACTIVE-U phase 1b/2 results.
Journal of Clinical Oncology2026-05-27
Neoadjuvant DAN-222 plus niraparib in high-risk HER2-negative breast cancer: Results from the I-SPY 2 adaptive platform trial.
Journal of Clinical Oncology2026-05-27
Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer.
2026-05-13
Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
2026-03-25
Abstract PS3-11-10: Neoadjuvant HSP90 inhibition with ganetespib significantly improves distant relapse-free survival in I-SPY2 patients with HER2-negative breast cancer with low expression of immune genes and no DNA repair deficiency
Clinical Cancer Research2026-02-17
Abstract PS1-01-09: Real-time monitoring for drug-induced interstitial lung disease with Trastuzumab Deruxtecan and Rilvegostomig combination therapy prevents persistent, symptomatic disease: Safety insights from the I-SPY2.2 platform trial
Clinical Cancer Research2026-02-17
Abstract RF5-06: Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial
Clinical Cancer Research2026-02-17
Abstract PD10-03: Subgroup analyses of VERITAC-2: A phase 3 trial of vepdegestrant, a PROTAC estrogen receptor (ER) degrader, versus fulvestrant in ER-positive/ human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC)
Clinical Cancer Research2026-02-17
Abstract PS2-11-06: Quiescent-like phenotype characterizes treatment-resistant early-stage HER2-negative breast cancers and suggests novel therapeutic targets; analysis of over 2000 patients from the I-SPY2 trial
Clinical Cancer Research2026-02-17
The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult Participants.
2026-01-19
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.
2025-10-24
Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
Frontiers in Oncology2025-07-24
A two-stage dual-task learning strategy for early prediction of pathological complete response to neoadjuvant chemotherapy for breast cancer using dynamic contrast-enhanced magnetic resonance images
Physics in Medicine and Biology2025-07-101 citations

94 more papers not shown